Research and the Bredesen Protocol

What is the Bredesen Protocol?

Video on the Science behind the Bredesen Protocol

Quick Background of the Protocol

 Professor Dale Bredesen, renowned for his work at the UCLA Department of Neurology as well as his position as a professor at the Buck Institute for Research on Aging in California, collaborated with fellow researchers at the Buck in 2011 to devise the “Bredesen Protocol.” 


This protocol is designed to address cognitive function through addressing underlying causes of the decline. The ReCODE Report is a personalised plan based on one’s test results.


Below, you will find published papers related to the Bredesen Protocol, as well as other studies that have demonstrated the effectiveness of lifestyle changes in preventing, slowing, or even reversing cognitive decline. Further details about the protocol’s background are provided below.

Published Papers by Professor Bredesen

Below are some of Professor Bredesen’s published papers (note, we are not making claims regarding the contents of these scientific papers but providing links with the published titles. We make no claims as to the efficacy of the protocol nor the published results). Further research is needed. Large scale random double blind placebo studies have yet to take place.

Professor Bredesen attempted in 2011 to start a trial in Australia (hear about this in the video linked at the end of this page), however, with the pace, structure and approval process for these types of studies, it is our hope that within the next 10-15 years we may see progress on a trial of this nature.


A small ethical board approved study on the Bredesen Protocol has concluded in the USA and results are below. Multi-site trials are currently in the participant recruitment process.


We encourage you to click on the hyperlinks below to read details on each published paper. If you do not understand the content or outcomes, you may print off each study or email the links to your doctor, a researcher, or other health care professional for interpretation. The Bredesen Protocol does not claim to be a “cure”.

Results of 2021 Trial of the Bredesen Protocol

Following on from the 100 cases of documented reversal of cognitive decline (10 cases being from our clients), the first ever trial with 25 participants aged 50-76 with MCI (pre-Alzheimer’s) or early dementia, which importantly was independently assessed, showed highly statistical improvements in cognition, functionality and even growth of parts of the Brain on MRI scan. 


The next step is the planned multi-site trial with a control group, but this 2021 trial is yet more evidence that the protocols may be effective.


Read more about the trial here (currently in pre-print – to be peer reviewed):

Reversal of Cognitive Decline 100 Case Studies

10 of the cases are our clients in New Zealand and Australia. 


Please read the study:


Bredesen et al.,J Alzheimers Dis Parkinsonism 2018, 8:5


DOI: 10.4172/2161-0460.1000450


Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease.
Theendakara V, Peters-Libeu CA, Bredesen DE, Rao RV
Mol Neurobiol. 2018 Jun;55(6):5243-5254. doi: 10.1007/s12035-017-0757-2. Epub 2017 Sep 6.


Reversal of cognitive decline in Alzheimer’s disease
Bredesen DE, Amos EC, Canick J Ackerley M, Raji C Fiala M7, Ahdidan J
Aging (Albany NY). 2016 Jun;8(6):1250-8. doi: 10.18632/aging.100981.


Inhalational Alzheimer’s disease: an unrecognized—and treatable—epidemic
Bredesen DE. Inhalational Alzheimer’s disease: an unrecognized—and treatable—epidemic.
Aging (Albany NY). 2016; 8:304-313.


Metabolic profiling distinguishes three subtypes of Alzheimer’s disease
Bredesen DE. Metabolic profiling distinguishes three subtypes of Alzheimer’s disease. Aging (Albany NY). 2015; 7:595-600.


Reversal of cognitive decline: A novel therapeutic program
Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY).
2014; 6:707-717.

Published papers by other authors based on or inspired by the "MEND"/Bredesen Protocol:

Personalised Medicine for Dementia: Collaborative Research of Multimodal Non-pharmacological Treatment with the UK National Health Service (NHS)
Chalfont G, Simpson J, Davies S, Morris D, Wilde R, Willoughby L, Milligan C. Personalised Medicine for Dementia: Collaborative Research of Multimodal Non-pharmacological Treatment with the UK National Health Service (NHS). OBM Geriatrics 2019;3(3):26; doi:10.21926/obm.geriatr.1903066.

Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals
Author(s): Dorothy Keine*, John Q. Walker, Brian K. Kennedy, Marwan N. Sabbagh.
Journal Name: Current Aging Science
Volume 11 , Issue 3 , 2018
DOI : 10.2174/1874609811666181019101430

Beyond Bredesen

Other researchers are discovering that lifestyle protocols may be showing a positive outcome on cognition.

Below are links to other studies relating to lifestyle factors and cognition:

The well known FINGER Study published in 2015 recruited 1260 older adults in Finland with increased risk of dementia “’Both the intervention group and the so-called placebo group, where we gave regular health advice, improved during the two years’, said Dr. Miia Kivipelto, MD, principal investigator and professor at Karolinska Institutet. ‘But the improvement was much higher in the intervention group, in all of the [cognitive] sub-domains: executive function for [information] processing (how quickly people are able to do different tasks) and complex memory tasks. And the risk of cognitive decline was 30% higher for the control group compared to the intervention group.’”


  • This evidence from the 2015 FINGER Study the has now developed into a World-Wide multi-site study called WW-FINGERS which states: “The FINGER trial is the first randomized controlled trial showing that it is possible to prevent cognitive decline using a multi-domain lifestyle intervention among older at-risk individuals. The results highlighted the value of addressing multiple dementia risk factors as a strategy to protect brain health, and promote overall health and functioning.”


  • UC Berkeley in California was awarded a US$47 million grant to include imaging for their arm of the FINGER Study called US-POINTER, which is a US$35 million Alzheimer’s Association sponsored 2 year study across multiple sites in the USA.


The 2017 Train the Brain Study in Italy of 113 MCI subjects aged 65–89 years
States: “In conclusion, a non pharmacological, combined physical and cognitive training in a social setting improves cognitive status of MCI subjects and improves indicators of brain health. The improvement is a small effect size. However, as pointed out by Ngandu et al.17, even small size effects in these initial stages may result in considerable gains in terms of public health. This underscores the importance of interventions aimed at multiple lifestyle factors as possible strategies to reduce or delay dementia conversion in MCI subjects, thus reducing dementia incidence.”
Maffei, L. et al. Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. Sci. Rep. 7, 39471; doi: 10.1038/srep39471 (2017).


A 2011 study “Exercise training increases size of hippocampus and improves memory” in the USA
States in the abstract: “The hippocampus shrinks in late adulthood, leading to impaired memory and increased risk for dementia. Hippocampal and medial temporal lobe volumes are larger in higher-fit adults, and physical activity training increases hippocampal perfusion, but the extent to which aerobic exercise training can modify hippocampal volume in late adulthood remains unknown. Here we show, in a randomized controlled trial with 120 older adults, that aerobic exercise training increases the size of the anterior hippocampus, leading to improvements in spatial memory. Exercise training increased hippocampal volume by 2%, effectively reversing age-related loss in volume by 1 to 2 y. We also demonstrate that increased hippocampal volume is associated with greater serum levels of BDNF, a mediator of neurogenesis in the dentate gyrus. Hippocampal volume declined in the control group, but higher preintervention fitness partially attenuated the decline, suggesting that fitness protects against volume loss.”


Kirk I. Erickson, Michelle W. Voss, Ruchika Shaurya Prakash, Chandramallika Basak, Amanda Szabo, Laura Chaddock, Jennifer S. Kim, Susie Heo, Heloisa Alves, Siobhan M. White, Thomas R. Wojcicki, Emily Mailey, Victoria J. Vieira, Stephen A. Martin, Brandt D. Pence, Jeffrey A. Woods, Edward McAuley, Arthur F. Kramer
Proceedings of the National Academy of Sciences Feb 2011, 108 (7) 3017-3022; DOI: 10.1073/pnas.1015950108


The World Health Organisation recognises and provides recommendations on risk factors and lifestyle behaviours and interventions to “delay or prevent cognitive decline and dementia” including: physical activity, nutrition, cognitive training, weight management, blood pressure, diabetes, cholesterol, etc.

Background of the Bredesen Protocol

Professor Dale Bredesen published over 200 papers during his 30 years of research in neuroscience and neurodegenerative diseases. You can read Professor Bredesen’s detailed CV for more information on his history. Below are explanations on the Protocol from Professor Bredesen’s book, trainings, and presentations, we are not making any of the below statements as our own.


In his book “The End of Alzheimer’s”, Professor Bredesen describes in his protocol over 36 parameters or “holes in the leaky roof” which may lead to degeneration of the brain, which (according to his theory) may be why mono-therapeutic drug approaches have thus far been ineffective, as plugging only one hole may not fix a “leaky roof”.


Professor Bredesen and other scientists theorize that Alzheimer’s Disease is triggered by multiple factors that lead to Beta Amyloid Plaques, Tau Tangles, brain cell death, and synapse retraction, which may be contributors to memory loss and Alzheimer’s Disease. These factors may be unique to each individual, and may include genetics, metabolic parameters such as glucose and insulin levels, low Vitamin B12 and Vitamin D levels, high homocysteine, inflammatory parameters such as CRP levels and/or reactions to heavy metals and toxins such as common moulds.


The series of case studies we co-published in 2018 detailing the reversal of symptoms of 100 cases of cognitive decline gives hope for further research. Over 1000 practitioners have been trained in the Bredesen Protocol, whilst being fully transparent that further clinical studies using the Bredesen Protocol are required.


If you wish to understand more about the protocol, please read Professor Bredesen’s book “The End of Alzheimer’s”, and check his company’s website for further scientific references.


If you are interested in our services, please contact us. We look forward to helping you and your loved ones and to working alongside all other dedicated practitioners.

Video below of Professor Bredesen presenting the science behind the protocols at TEDx Manhattan Beach

Great explainer video by “The Worthless Professor” on what is the Bredesen Protocol. Be sure to watch all 4 videos in the series.

Scroll to Top